title: Effects of thrombolysis for acute stroke in patients with pre-existing disability.
abstract: BACKGROUND
  Thrombolysis for acute stroke is beneficial in selected patients. Because clinical trials generally exclude patients with pre-existing disability, this subgroup of patients has not been studied. We examined the outcomes after thrombolysis of patients with and without disability before their stroke.
  
  
  METHODS
  We prospectively followed 112 consecutive patients with acute ischemic stroke who were given intravenous thrombolysis treatment according to published protocols. Three-month outcomes of the patients with pre-existing disability (defined as a prestroke score of 2 or more on the modified Rankin scale [MRS]) were compared with those of patients without pre-existing disability (defined as a prestroke MRS score of 0 or 1) and with those of 168 patients similarly treated in the National Institute of Neurological Disorders and Stroke trial.
  
  
  RESULTS
  At 3 months after the stroke, patients with pre-existing disability (21% of the 112) had a higher mortality rate than those without (33% v. 14%) (odds ratio 3.2, 95% confidence interval 1.0-10.1) and worse function (median MRS score 3 v. 2, p = 0.03). However, there was little difference between the 2 groups in neurologic impairment among the survivors (median score on the National Institutes of Health stroke scale 4 v. 2, p = 0.41) or in the total proportion of those with an MRS score of 0 or 1 or, for those with a prestroke score greater than 1, a return to the prestroke score (42% v. 41%, p = 0.87).
  
  
  CONCLUSIONS
  Although the true effectiveness of thrombolysis for acute stroke in patients with pre-existing disability is not known, treated patients appear able to return to their prestroke level of function as often as patients without pre-existing disability, despite a significantly higher mortality rate.
authors.affiliation: London Health Sciences Centre, Department of Clinical Neurological Sciences, and the University of Western Ontario, London, Ont.
authors.forename: R Blaine Taylor
authors.initials: RB
authors.lastname: Foell
authors.forename: Brian
authors.initials: B
authors.lastname: Silver
authors.forename: Jose G
authors.initials: JG
authors.lastname: Merino
authors.forename: Edward H
authors.initials: EH
authors.lastname: Wong
authors.forename: Bart M
authors.initials: BM
authors.lastname: Demaerschalk
authors.forename: Fali
authors.initials: F
authors.lastname: Poncha
authors.forename: Arturo
authors.initials: A
authors.lastname: Tamayo
authors.forename: Vladimir
authors.initials: V
authors.lastname: Hachinski
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D006233:Persons with Disabilities; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D020521:Stroke / Q000453:epidemiology; D000071939:Stroke Rehabilitation; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator